Press Releases
Bioxodes to present at Biotech Showcase™ 2023
Bioxodes to present at Biotech Showcase™ 2023 about its breakthrough drug candidate Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Gosselies, Belgium, December 15th, 2022
Bioxodes a clinical-stage biotechnology company announces today that Bioxodes’ CEO, Marc Dechamps, will present a corporate overview at Biotech Showcase™ on Tuesday, January 10, 2023, at 11:30 am PST. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference.
Bioxodes will be available to meet potential partners, collaborators, and investors. Meetings can be requested through the Biotech Showcase partnering platform or by contacting Bioxodes at info@bioxodes.com.
About Bioxodes
Bioxodes specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since it was founded in 2013, Bioxodes has developed its own flagship program based around its Ir-CPI molecule. Ir-CPI is a first-in-class drug candidate aimed at patients with hemorrhagic stroke. The company, which is based in Gosselies in Belgium, has so far secured €22.1 million in funding from Belgian investment funds and business angels, including €8.5 million in non-dilutive funding from the Walloon region. Bioxodes holds both granted and pending patents associated with Ir-CPI in the European Union and the United States.
Company contact
Marc Dechamps, CEO
info@bioxodes.com